Establishment of FAP-overexpressing Cells for FAP-targeted Theranostics

Abstract

Objective

Fibroblast activation protein (FAP) has been widely studied and exploited for its clinical applications. One of the difficulties in interpreting reports of FAP-targeted theranostics is due to the lack of accurate controls, making the results less specific and less confirmative. This study aimed to establish a pair of cell lines, in which one highly expresses FAP (HT1080-hFAP) and the other has no detectable FAP (HT1080-vec) as control, to accurately evaluate the specificity of the FAP-targeted theranostics in vitro and in vivo.

Methods

The cell lines of the experimental group (HT1080-hFAP) and no-load group (HT1080-vec) were obtained by molecular construction of the recombinant plasmid pIRES-hFAP. The expression of hFAP in HT1080 cells was detected by PCR, Western blotting and flow cytometry. CCK-8, Matrigel transwell invasion assay, scratch test, flow cytometry and immunofluorescence were used to verify the physiological function of FAP. The activities of human dipeptidyl peptidase (DPP) and human endopeptidase (EP) were detected by ELISA in HT1080-hFAP cells. PET imaging was performed in bilateral tumor-bearing nude mice models to evaluate the specificity of FAP.

Results

RT-PCR and Western blotting demonstrated the mRNA and protein expression of hFAP in HT1080-hFAP cells but not in HT1080-vec cells. Flow cytometry confirmed that nearly 95% of the HT1080-hFAP cells were FAP positive. The engineered hFAP on HT1080 cells had its ability to retain enzymatic activities and a variety of biological functions, including internalization, proliferation-, migration-, and invasion-promoting activities. The HT1080-hFAP xenografted tumors in nude mice bound and took up ⁶⁸GA-FAPI-04 with superior selectivity. High image contrast and tumor-organ ratio were obtained by PET imaging. The HT1080-hFAP tumor retained the radiotracer for at least 60 min.

Conclusion

This pair of HT1080 cell lines was successfully established, making it feasible for accurate evaluation and visualization of therapeutic and diagnostic agents targeting the hFAP.

Keywords

fibroblast activation protein / ⁶⁸GA-FAPI-04 / reporter gene / positron emission computed tomography image

References

[1] AndersonNM, SimonMC. The tumor microenvironment. Curr Biol, 2020, 30(16): R921-R925

[2] Roma-RodriguesC, MendesR, BaptistaPV, et al.. Targeting Tumor Microenvironment for Cancer Therapy. Int J Mol Sci, 2019, 20(4): 840

[3] BussardKM, MutkusL, StumpfK, et al.. Tumor-associated stromal cells as key contributors to the tumor microenvironment. Breast Cancer Res, 2016, 18(1): 84

[4] AltmannA, HaberkornU, SivekeJ. The Latest Developments in Imaging of Fibroblast Activation Protein. J Nucl Med, 2021, 62(2): 160-167

[5] NurmikM, UllmannP, RodriguezF, et al.. In search of definitions: Cancer-associated fibroblasts and their markers. Int J Cancer, 2020, 146(4): 895-905

[6] GascardP, TlstyTD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev, 2016, 30(9): 1002-1019

[7] LinY, CaiQ, ChenY, et al.. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase. Hepatology, 2022, 75(1): 28-42

[8] HanC, LiuT, YinR. Biomarkers for cancer-associated fibroblasts. Biomark Res, 2020, 8(1): 64

[9] El KhouryJ, KurbanM, KibbiAG, et al.. Fibroblast-activation protein: valuable marker of cutaneous epithelial malignancy. Arch Dermatol Res, 2014, 306(4): 359-365

[10] JacobM, ChangL, PuréE. Fibroblast activation protein in remodeling tissues. Curr Mol Med, 2012, 12(10): 1220-1243

[11] Juillerat-JeanneretL, TafelmeyerP, GolshayanD. Fibroblast activation protein-alpha in fibrogenic disorders and cancer: more than a prolyl-specific peptidase?. Expert Opin Ther Targets, 2017, 21(10): 977-991

[12] FitzgeraldAA, WeinerLM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev, 2020, 39(3): 783-803

[13] PuréE, BlombergR. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene, 2018, 37(32): 4343-4357

[14] HamsonEJ, KeaneFM, TholenS, et al.. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl, 2014, 8(5–6): 454-463

[15] KeaneFM, NadviNA, YaoTW, et al.. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α. Febs j, 2011, 278(8): 1316-1332

[16] De DeckerA, VliegenG, Van RompaeyD, et al.. Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP). ACS Med Chem Lett, 2019, 10(8): 1173-1179

[17] WangH, WuQ, LiuZ, et al.. Downregulation of FAP suppresses cell proliferation and metastasis through PTEN/PI3K/AKT and Ras-ERK signaling in oral squamous cell carcinoma. Cell Death Dis, 2014, 5(4): e1155

[18] JiaJ, MartinTA, YeL, et al.. FAP-α (Fibroblast activation protein-α) is involved in the control of human breast cancer cell line growth and motility via the FAK pathway. BMC Cell Biol, 2014, 15: 16

[19] NingX, WirajaC, ChewWTS, et al.. Transdermal delivery of Chinese herbal medicine extract using dissolvable microneedles for hypertrophic scar treatment. Acta Pharm Sin B, 2021, 11(9): 2937-2944

[20] LayAJ, ZhangHE, MccaughanGW, et al.. Fibroblast activation protein in liver fibrosis. Front Biosci (Landmark Ed), 2019, 24(1): 1-17

[21] SteinS, WeberJ, Nusser-SteinS, et al.. Deletion of fibroblast activation protein provides atheroprotection. Cardiovasc Res, 2021, 117(4): 1060-1069

[22] MousaviMJ, FarhadiE, VodjganiM, et al.. Role of Fibroblast Activation Protein Alpha in Fibroblast-like Synoviocytes of Rheumatoid Arthritis. Iran J Allergy Asthma Immunol, 2021, 20(3): 338-349

[23] KratochwilC, FlechsigP, LindnerT, et al.. (68)Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med, 2019, 60(6): 801-805

[24] MeyerC, DahlbomM, LindnerT, et al.. Radiation Dosimetry and Biodistribution of (68)Ga-FAPI-46 PET Imaging in Cancer Patients. J Nucl Med, 2020, 61(8): 1171-1177

[25] SolliniM, KirienkoM, GelardiF, et al.. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging, 2021, 48(13): 4396-4414

[26] LoktevA, LindnerT, MierW, et al.. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med, 2018, 59(9): 1423-1429

[27] LindnerT, LoktevA, AltmannA, et al.. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med, 2018, 59(9): 1415-1422

[28] BusekP, MateuR, ZubalM, et al.. Targeting fibroblast activation protein in cancer–Prospects and caveats. Front Biosci (Landmark Ed), 2018, 23(10): 1933-1968

[29] XuM, ZhangP, DingJ, et al.. Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy. J Nucl Med, 2022, 63(6): 952-958

[30] LindnerT, LoktevA, AltmannA, et al.. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J Nucl Med, 2018, 59(9): 1415-1422

[31] BughdaR, DimouP, D’souzaRR, et al.. Fibroblast Activation Protein (FAP)-Targeted CAR-T Cells: Launching an Attack on Tumor Stroma. Immunotargets Ther, 2021, 10: 313-323

[32] KuzetSE, GaggioliC. Fibroblast activation in cancer: when seed fertilizes soil. Cell Tissue Res, 2016, 365(3): 607-619

[33] JungHJ, NamEH, ParkJY, et al.. Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor. Bioorg Med Chem Lett, 2021, 37: 127846

[34] BrennenWN, RosenDM, ChauxA, et al.. Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. Prostate, 2014, 74(13): 1308-1319

[35] DengLJ, WangLH, PengCK, et al.. Fibroblast Activation Protein a Activated Tripeptide Bufadienolide Antitumor Prodrug with Reduced Cardiotoxicity. J Med Chem, 2017, 60(13): 5320-5333

[36] RügerR, TansiFL, RabenholdM, et al.. In vivo near-infrared fluorescence imaging of FAP-expressing tumors with activatable FAP-targeted, single-chain Fv-immunoliposomes. J Control Release, 2014, 186: 1-10

[37] TansiF L, RügerR, BöhmC, et al.. Activatable bispecific liposomes bearing fibroblast activation protein directed single chain fragment/Trastuzumab deliver encapsulated cargo into the nuclei of tumor cells and the tumor microenvironment simultaneously. Acta Biomater, 2017, 54: 281-293

[38] XiaQ, GengF, ZhangFF, et al.. Enhancement of fibroblast activation protein α-based vaccines and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice. Vaccine, 2016, 34(38): 4526-4535

[39] XiaQ, ZhangFF, GengF, et al.. Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein a by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model. Cancer Immunol Immunother, 2016, 65(5): 613-624

[40] XiaQ, GengF, ZhangFF, et al.. Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein a-based DNA vaccine in tumor-bearing mice with murine breast carcinoma. Immunopharmacol Immunotoxicol, 2017, 39(1): 37-44

[41] WangLC, LoA, SchollerJ, et al.. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol Res, 2014, 2(2): 154-166

[42] HiltbrunnerS, BritschgiC, SchuberthP, et al.. Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial. Ann Oncol, 2021, 32(1): 120-121

[43] FanMH, ZhuQ, LiHH, et al.. Fibroblast Activation Protein (FAP) Accelerates Collagen Degradation and Clearance from Lungs in Mice. J Biol Chem, 2016, 291(15): 8070-8089

[44] Sánchez-GarridoMA, HabeggerKM, ClemmensenC, et al.. Fibroblast activation protein (FAP) as a novel metabolic target. Mol Metab, 2016, 5(10): 1015-1024

[45] YangX, LinY, ShiY, et al.. FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in the Tumor Microenvironment via STAT3-CCL2 Signaling. Cancer Res, 2016, 76(14): 4124-4135

[46] GieselFL, KratochwilC, LindnerT, et al.. (68)Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers. J Nucl Med, 2019, 60(3): 386-392

[47] LindnerT, AltmannA, GieselF, et al.. (18)F-labeled tracers targeting fibroblast activation protein. EJNMMI Radiopharm Chem, 2021, 6(1): 26

[48] BairdSK, AllanL, RennerC, et al.. Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways. Clin Exp Metastasis, 2015, 32(5): 507-516